Recent advances: parenteral nutrition support.
Even though there is an abundance of research related to the clinical and physiologic effects of parenteral nutrition and specific nutritional substrates, few new products have been released for clinical use. This review illustrates some of the directions being taken in the future development of parenteral nutrition products and some new perspectives related to the current effects (or lack of effects) of TPN. When considering the individual effects of specific nutrient substrates (arginine, glutamine, LCTs, MCTs, SCFAs) as reviewed here, it becomes apparent that the infusion of parenteral nutrition has the potential to produce a variety of metabolic responses that could be both beneficial and harmful. These effects depend on the type and quantity of substance infused as well as the disease and clinical condition of the patient. This also is true for those substances (GH, IGF-1) being evaluated to direct the effects of TPN infusions in a manner that improves protein accretion and supports the immunologic response of the body. At best, these investigations are producing a great amount of new and more specific information about the metabolic response to illness and the effects of TPN and individual substrate on that response.
Mattox
T W
TW
H. Lee Moffitt Cancer Center and Research Institute, Colleges of Pharmacy, University of Florida, Tampa, USA.
Bertch
K E
KE
Mirtallo
J M
JM
Strausberg
K M
KM
Cuddy
P G
PG
D001120:Arginine / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D005217:Fat Emulsions, Intravenous / Q000378:metabolism / Q000494:pharmacology; D005973:Glutamine / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D006133:Growth Substances / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism / Q000494:pharmacology; D015399:Nursing Research; D010288:Parenteral Nutrition / Q000639:trends*; D010289:Parenteral Nutrition, Total / Q000639:trends
D005217:Fat Emulsions, Intravenous; D006133:Growth Substances; D005973:Glutamine; D007334:Insulin-Like Growth Factor I; D001120:Arginine